Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Coherus_BioSciences
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Rob_Ross
|
| gptkbp:collaboratedWith |
gptkb:Merck
gptkb:Novartis |
| gptkbp:developedBy |
antibody-based therapies
|
| gptkbp:focusesOn |
immuno-oncology
cancer therapeutics |
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Surface Oncology
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:NASDAQListed |
yes
|
| gptkbp:notableProduct |
gptkb:SRF114
gptkb:SRF388 gptkb:SRF617 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
gptkb:SURF
|
| gptkbp:website |
https://surfaceoncology.com/
|
| gptkbp:bfsParent |
gptkb:Atlas_Venture
gptkb:David_Grayzel |
| gptkbp:bfsLayer |
6
|